These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Botulinum toxins in the treatment of primary focal dystonias. Truong D J Neurol Sci; 2012 May; 316(1-2):9-14. PubMed ID: 22336699 [TBL] [Abstract][Full Text] [Related]
45. [The clinical usefulness of botulinum toxin type A for spasmodic torticollis and facial spasm]. Mezaki T; Kaji R; Kimura J; Osame M; Mizuno Y; Hirayama K; Maruyama S; Iwata M; Kanazawa I; Kinoshita M No To Shinkei; 1995 Aug; 47(8):749-54. PubMed ID: 7546919 [TBL] [Abstract][Full Text] [Related]
46. Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? Jinnah HA; Comella CL; Perlmutter J; Lungu C; Hallett M; Toxicon; 2018 Jun; 147():89-95. PubMed ID: 28888929 [TBL] [Abstract][Full Text] [Related]
48. Botulinum toxin treatment of secretory disorders. Naumann M; Jost W Mov Disord; 2004 Mar; 19 Suppl 8():S137-41. PubMed ID: 15027066 [TBL] [Abstract][Full Text] [Related]
49. [Contribution of botulinum toxin to maxillo-facial surgery]. Batifol D; de Boutray M; Goudot P; Lorenzo S Rev Stomatol Chir Maxillofac Chir Orale; 2013 Apr; 114(2):72-8. PubMed ID: 23838244 [TBL] [Abstract][Full Text] [Related]
50. An in vivo analysis of the effect and duration of treatment with botulinum toxin type A using digital image speckle correlation. Bhatnagar D; Conkling N; Rafailovich M; Phillips BT; Bui DT; Khan SU; Dagum AB Skin Res Technol; 2013 Aug; 19(3):220-9. PubMed ID: 23565582 [TBL] [Abstract][Full Text] [Related]
51. Consideration of Muscle Depth for Botulinum Toxin Injections: A Three-Dimensional Approach. Kaplan JB Plast Surg Nurs; 2017; 37(1):32-38. PubMed ID: 28244963 [TBL] [Abstract][Full Text] [Related]
52. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474 [TBL] [Abstract][Full Text] [Related]
53. [Use of intracutaneous or subcutaneous botulinum toxin for postherpetic neuralgia]. Halb L; Amann BJ; Bornemann-Cimenti H Nervenarzt; 2017 Apr; 88(4):408-414. PubMed ID: 27924350 [TBL] [Abstract][Full Text] [Related]
54. Cosmetic oculofacial applications of botulinum toxin: a report by the American Academy of Ophthalmology. Kaltreider SA; Kennedy RH; Woog JJ; Bradley EA; Custer PL; Meyer DR; ; Ophthalmology; 2005 Jun; 112(6):1159-67. PubMed ID: 15936443 [TBL] [Abstract][Full Text] [Related]
55. Development of botulinum toxin therapy. Hermanowicz N; Truong DD West J Med; 1995 Nov; 163(5):472-3. PubMed ID: 8533413 [No Abstract] [Full Text] [Related]
56. Botulinum toxin therapy in hemifacial spasm: clinical and electrophysiologic studies. Geller BD; Hallett M; Ravits J Muscle Nerve; 1989 Sep; 12(9):716-22. PubMed ID: 2630907 [TBL] [Abstract][Full Text] [Related]
57. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations. Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565 [TBL] [Abstract][Full Text] [Related]
58. Botulinum toxin-A for the treatment of hemifacial spasm. Cuevas C; Madrazo I; Magallón E; Zamorano C; Neri G; Reyes E Arch Med Res; 1995; 26(4):405-8. PubMed ID: 8555735 [TBL] [Abstract][Full Text] [Related]
59. Botulinum Toxin for the Treatment of Neuropathic Pain. Park J; Park HJ Toxins (Basel); 2017 Aug; 9(9):. PubMed ID: 28837075 [TBL] [Abstract][Full Text] [Related]
60. Use of botulinum toxin in the neurology clinic. Lim EC; Seet RC Nat Rev Neurol; 2010 Nov; 6(11):624-36. PubMed ID: 21045798 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]